RT Journal Article
SR Electronic
T1 Quantifying the relationship between SARS-CoV-2 viral load and infectiousness
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.07.21256341
DO 10.1101/2021.05.07.21256341
A1 Aurélien Marc
A1 Marion Kerioui
A1 François Blanquart
A1 Julie Bertrand
A1 Oriol Mitjà
A1 Marc Corbacho-Monné
A1 Michael Marks
A1 Jérémie Guedj
YR 2021
UL http://medrxiv.org/content/early/2021/05/08/2021.05.07.21256341.abstract
AB The relationship between SARS-CoV-2 viral load and infectiousness is not known. Using data from a prospective cohort of index cases and high-risk contact, we reconstructed by modelling the viral load at the time of contact and the probability of infection. The effect of viral load was particularly large in household contacts, with a transmission probability that increased to as much as 37% when the viral load was greater than 10 log10 copies per mL. The transmission probability peaked at symptom onset in most individuals, with a median probability of transmission of 15%, that hindered large individual variations (IQR: [8, 37]). The model also projects the effects of variants on disease transmission. Based on the current knowledge that viral load is increased by 2 to 4-fold on average, we estimate that infection with B1.1.7 virus could lead to an increase in the probability of transmission by 8 to 17%.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study has received financialsupport from the National Research Agency (ANR) through the ANR-Flashcall for COVID-19 (Grant ANR-20-COVI-0018) and the Bill and Melinda GatesFoundation under Grant Agreement INV-017335. The original trial was funded by a crowdfunding campaign YoMeCorono (https://www.yomecorono.com/), and Generalitat de Catalunyawith support for laboratory equipment fromFoundation Dormeur. We thank Samuel Alizon, Xavier Duvaland Xavier de Lamballerie for helpful discussions.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data used in this study originate from an original clinical study. Details on the study can be found in : Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. The trial protocol and subsequent amendments were approved by the institutional review board at Hospital Germans Trias i Pujol and the Spanish Agency of Medicines and Medical Devices. All the participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset used for this study is provided.